Cancer Treatment Research federal funding in FY2024

Cancer Treatment Research and FY2024 as a USAspending pair

Cancer Treatment Research in FY2024 obligated $7,619,220,887.20 on USAspending.gov. Keep both keys in the citation: the CFDA title Cancer Treatment Research and the fiscal year 2024. 87.0% of $8,755,707,172.30 is arithmetic on two packet facts, not a ranking of fiscal years as winners or losers. The CFDA title is CANCER TREATMENT RESEARCH. This packet does not split therapeutic modalities or disease sites inside the year cell.

Read /programs/93.395/ (CFDA 93.395) for the program rollup, /fiscal-years/2024/ (FY2024 federal spending) for the year rollup, /programs/ (All programs) for every CFDA hub, and /ties/ (All spending ties) for the rest of the join list. Do not add those pages into $7,619,220,887.20. Recipients are unpublished. Two thousand six hundred seventy-one FY2024 awards is not 2,671 unique trials. Competing continuations add rows.

Program coding for Cancer Treatment Research

USAspending labels CFDA 93.395 as Cancer Treatment Research. That code produced $7,619,220,887.20 when crossed with fiscal year 2024. The program-wide hub does not require a FY2024 filter. The year hub does not require this CFDA. Only this tie applies both filters. The CFDA title is CANCER TREATMENT RESEARCH. This packet does not split therapeutic modalities or disease sites inside the year cell. FY2024 figures can still move after deobligations or recoveries.

The program extract-wide obligation total is $8,755,707,172.30 across 3,545 award records. FY2024 is 87.0% of that book. Other fiscal-year rows for CFDA 93.395 are separate cells. Do not fold /programs/ into this join as if every CFDA were this one. Keep 93.395.

FY2024 cancer-treatment research obligations are not trial enrollments

FY2024 on USAspending.gov is a federal fiscal year, not a calendar year and not a state fiscal year. $7,619,220,887.20 is the Cancer Treatment Research slice of that year in this extract, not the government-wide FY2024 total. FY2024 figures can still move after deobligations or recoveries. Prefer /fiscal-years/2024/ if the live year table moved. Outlays are unpublished.

An obligation is a legal commitment recorded on an award. An outlay is a payment from the Treasury. $7,619,220,887.20 is the former for Cancer Treatment Research in FY2024. Later deobligations, recoveries, or payment schedules can change what leaves the Treasury without this join rewriting itself into a cash register. This page reports $7,619,220,887.20 as given.

2,671 FY2024 awards are not 2,671 clinical trials

2,671 is the FY2024 award-record count published on this pair. 3,545 is the program-extract award-record count across years. Dividing $7,619,220,887.20 by 3,545 would mix a one-year dollar total with a multi-year row count, so this page does not publish that ratio as a typical award. Unique recipients are unpublished. Two thousand six hundred seventy-one FY2024 awards is not 2,671 unique trials. Competing continuations add rows.

Commitment totals versus cash paid

Budget justifications, program evaluation reports, and press releases answer other questions. They are not the source of this cell. If a chart mixes cancer centers support grants, a CMS oncology spend, or a named-investigator list with CFDA 93.395 in FY2024, the chart has left this join. Investigator names, trial titles, and campuses are unpublished on this packet.

Keep the citation narrow: CFDA 93.395 and fiscal year 2024 on USAspending.gov, obligations only, with no invented recipients. Investigator names, trial titles, and campuses are unpublished on this packet.

Cancer Treatment Research in FY2024 is a pair, not a ranking of programs and not a ranking of fiscal years. Later bulk files can move the dollars; prefer the live CFDA 93.395 hub and the FY2024 hub when this snapshot and the live tables diverge.

Questions

How much did Cancer Treatment Research show in federal obligations in FY2024?

USAspending.gov records $7,619,220,887.20 in Cancer Treatment Research obligations for FY2024 (CFDA 93.395). That is an obligation aggregate for the program-year pair, not an outlay and not the government-wide FY2024 total. Original filings remain on USAspending.gov.

Is Cancer Treatment Research FY2024 cash already paid to trial sites?

No. $7,619,220,887.20 is a yearlyTrend obligation sum, not an outlay. Payments from the Treasury can lag or differ. This packet has no outlay total for Cancer Treatment Research in FY2024. Original filings remain on USAspending.gov.

Do 2,671 awards mean 2,671 clinical trials?

No. 2,671 is the FY2024 award-record count on this pair, not a published unique-recipient census. The program extract lists 3,545 awards across years. Modifications can add rows. Original filings remain on USAspending.gov. Keep both the CFDA number and the fiscal year in the citation.

Which pages parent Cancer Treatment Research FY2024?

The CFDA 93.395 hub is the program parent. The FY2024 federal-spending hub is the year parent. All programs lists CFDA hubs. All spending ties lists other pairs. Prefer those tables after later ingests; this page quotes Cancer Treatment Research × FY2024 at $7,619,220,887.20.